US · Healthcare · Biotechnology
EPS came in at -0.54 against a street estimate of -0.39 — a miss of 38.5%.
Analysts rate Nkarta Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $10.83.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 15.09% |
| BlackRock Inc | 8.80% |
| NEA Management Company, LLC | 4.98% |
| Samsara BioCapital, LLC | 4.90% |
| SR ONE CAPITAL MANAGEMENT, LP | 4.65% |
| GSK PLC | 4.40% |
| Monaco Asset Management | 3.31% |
| Vanguard Capital Management, LLC | 3.11% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nkarta Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.